Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Apricot Capital

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 22
Average round size
The average size of a deal this fund participated in
Portfolio companies 16
Rounds per year 2.75
Lead investments 4
Exits 1
Key employees 2

Areas of investment

  • Health Care
  • Biotechnology
  • Manufacturing
  • Medical
  • Medical Device

In 2010 was created Apricot Capital, which is appeared as VC. The venture was found in North America in United States. The main department of described VC is located in the Boston.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Apricot Capital, startups are often financed by Versant Ventures, Tavistock Life Sciences, 5AM Ventures. The meaningful sponsors for the fund in investment in the same round are Zhongjin Qichen, Where Angels Fund, Walter Winshall. In the next rounds fund is usually obtained by Romulus Capital, SeedInvest, New Enterprise Associates.

The overall number of key employees were 2.

Speaking about the real fund results, this VC is 10 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2019. The top amount of exits for fund were in 2014. Comparing to the other companies, this Apricot Capital performs on 11 percentage points more the average number of lead investments.

The fund has specific favorite in a number of founders of portfolio startups. Among the most successful fund investment fields, there are Education, Mobile. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Bellen, Placester, Ambrx For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
100+ Accelerator New York, New York, United States
Canon BioMedical Melville, New York, United States
Canopy San Diego California, San Diego, United States
Company Ventures New York, New York, United States
Geshang Licai Beijing, Beijing, China
GINcapital Mexico, Naucalpan de Juárez, State of Mexico
Good Company Israel, Tel Aviv, Tel Aviv District
Granot Ventures Israel, Tel Aviv, Tel Aviv District
Japan Industrial Partners Japan, Tokyo
Lena Street Chicago, Illinois, United States
MIQ China, Hangzhou, Zhejiang
MKS Geneva, Geneva, Switzerland
National City Equity Partners Cleveland, Ohio, United States
Sprig Investment LLC -
Tradecraft Capital Austin, Texas, United States
Trident -
Waverly Capital -
Wee Hur Holdings Central, Central Region, Singapore
Xizang Zhengji Jijin Guanli -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Advanced Materials
05 Sep 2022 Hangzhou, Zhejiang, China

Axiata Bio

Health Care
Medical Device
$13M01 Aug 2022 Suzhou, Jiangsu, China

Qihe Biotech

Food and Beverage
21 Mar 2022 Zhangdian District, Shandong, China


31 Aug 2021 Shanghai, Shanghai, China

GRIT Biotechnology

Health Care
Medical Device
14 Jul 2021 Shanghai, Shanghai, China

Forerunner Medical

Medical Device
$15M05 Mar 2021 Shanghai, China

Medilink Therapeutics

$50M01 Mar 2021 Gusu District, Jiangsu, China


Health Care
$35M03 Nov 2020 Dongcheng District, Beijing, China

Shenqi Medical

Health Care
Medical Device
$15M25 Aug 2020 Shanghai, Shanghai, China
Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development

– Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development
– The financing includes a series-A1 round led by Apricot Capital, and a series-A2 round co-led by Loyal Valley Capital and Qiming Venture Partners.
– Medilink Therapeutics was established in 2020 by a sophisticated team of industrial veterans.
– Medilink has high ambitions for its ADC R&D to be globally competitive, and meet the needs of global patients in the future.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Apricot Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: